Acquired Company
XOMA Royalty Corporation acquired Mural Oncology plc for $2.035 per share in cash, with an additional up to $0.205 per share contingent on closing net cash, the acquisition completed December 5, 2025.
Mural Oncology plc is a pioneering biotechnology company dedicated to developing targeted therapies for solid tumors, addressing significant unmet needs in oncology. The company utilizes proprietary platforms to boost immune system engagement, advancing a strong pipeline of innovative drug candidates designed to enhance patient outcomes. With a strategic focus on clinical excellence and collaborative partnerships, Mural is committed to delivering transformative precision medicine solutions that elevate cancer care and set new benchmarks in treatment efficacy. Show more
10 EARLSFORT TERRACE, DUBLIN, IRELAND, D02 T380, Dublin, D02 T380, USA
Market Cap
35.38M
52 Wk Range
$1.53 - $2.30
Previous Close
$2.04
Open
$2.04
Volume
N/A
Day Range
$2.04 - $2.04
Enterprise Value
-19.94M
Cash
58.87M
Avg Qtr Burn
-18.48M
Insider Ownership
13.41%
Institutional Own.
46.57%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nemvaleukin alfa +/- pembrolizumab Details Mucosal melanoma | Failed Discontinued | |
Nemvaleukin alfa (ALKS 4230) (IL-2) Details Solid tumor/s, Cancer | Failed Discontinued | |
Nemvaleukin alfa + pembrolizumab Details Ovarian cancer, Solid tumor/s, Cancer, Platinum-resistant ovarian cancer | Failed Discontinued |